Results 231 to 240 of about 16,590,594 (260)

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1181-1194, November 2026.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus   +7 more
wiley   +1 more source

Plasmepsins as Antimalarial Drug Targets—Then, Now, and the Future

open access: yesMedicinal Research Reviews, Volume 46, Issue 6, Page 1574-1602, November 2026.
ABSTRACT Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential
Brad E. Sleebs
wiley   +1 more source

A US-Based Multi-Site Pilot to Screen Hepatitis B Surface Antigen-Positive Patients for Hepatitis D. [PDF]

open access: yesJ Viral Hepat
Li M   +13 more
europepmc   +1 more source

Transcription of hepatitis B surface antigen shifts from cccDNA to integrated HBV DNA during treatment. [PDF]

open access: yesJ Clin Invest
Taddese M   +15 more
europepmc   +1 more source

Mindray CL-900i assay: An effective assay for hepatitis B surface antigen screening with superior specificity. [PDF]

open access: yesIJID Reg
Nasrallah GK   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy